Ultragenyx to Sell Rare Pediatric Disease Voucher for $210M

Shots: Ultragenyx has entered into a definitive agreement to sell a Rare Pediatric Disease PRV for $210M, provide Ultragenyx with significant non-dilutive capital to advance therapies for rare & ultra-rare diseases Rare Pediatric Disease PRV was received following FDA approval of Genglycos (pariglasgene brecaparvovec-opnr), the first treatment targeting the underlying cause of glycogen storage disease type Ia The PRV transaction remains subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act Ref: Globenewswire |   Image: Ultragenyx  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Ultragenyx to Sell Rare Pediatric Disease Voucher for $210M appeared first on PharmaShots.